LAE 109
Alternative Names: LAE-109Latest Information Update: 03 Oct 2022
At a glance
- Originator Laekna Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Sep 2022 LAE 109 is available for licensing as of 14 Sep 2022. https://www.laekna.com/ (Laekna Therapeutics website, September 2022).
- 14 Sep 2022 Preclinical trials in Cancer in China (Parenteral) prior to September 2022 (Laekna Therapeutics pipeline, September 2022)